Table 1.
Information of ABMSC therapy
| Included studies | Stage (Child-Pugh) | Patients (Con/Exp) | Therapeutic regimen (administration route) | Cell dose | Enrollment period | Follow-up (week) | Parameter types |
|---|---|---|---|---|---|---|---|
| Chen et al. [23] | B–C | 34/33 | RT+ABMSC (HA) | 3.0–5.0 × 106 | November 2008–April 2012 | 24 | TBIL, ALB, ALT, PT, PTA, MELD, Child-Pugh |
| Cui [24] | B–C | 22/18 | RT+ABMSC (HA) | 5.6 × 108–1.8 × 1011 | October 2011–December 2013 | 12 | TBIL, ALB, ALT, PTA, CS, LFI, MELD, Child-Pugh |
| Hou et al. [25] | ND | 25/25 | RT+ABMSC (HA) | ND | November 2009–February 2011 | 16 | TBIL, ALB, ALT, PT, MELD |
| Jiang [26] | B–C | 13/12 | RT+ABMSC (HA) | 2.1–6.8 × 1010 | July 2009–June 2011 | 24 | TBIL, ALB, ALT, AST, PT, CS |
| Jin et al. [27] | B–C | 20/20 | RT+ABMSC (HA) | 4.0 × 107–3.0 × 108 | April 2009–April 2010 | 12 | TBIL, ALB, PTA |
| Liu et al. [19] | B–C | 37/40 | RT+ABMSC (HA) | 3.2 × 1010–1.6 × 1011 | April 2009–October 2010 | 4 | TBIL, ALB, ALT, AST, PT |
| Mao et al. [28] | A–C | 32/32 | RT+ABMSC (HA) | > 109 | January 2009–January 2012 | 4 | TBIL, ALB, ALT, PT |
| Peng et al. [2] | ND | 77/39 | RT+ABMSC (HA) | 3.4 ± 3.8 × 108 | May 2005–June 2009 | 4 | TBIL, ALB, ALT, PT, MELD |
| Wu et al. [29] | B–C | 25/27 | RT+ABMSC (HA) | 1.0 × 108–9 | January 2013–January 2015 | 24 | TBIL, ALT, AST, CS, LFI, MELD, Child-Pugh |
| Xu et al. [20] | ND | 29/27 | RT+ABMSCs (HA) | 8.5 ± 3.3 × 108 | March 2012–December 2012 | 24 | ALB, ALT, MELD |
Abbreviations: Con control group (RT alone group), Exp experimental group (RT plus ABMSC therapy), RT routing therapy, ABMSC autologous bone marrow stem cell, ND non-determined, HA hepatic artery